We are thrilled to announce our plans to commence operations in the cities of Abu Dhabi and Al-Ain, in the United Arab Emirates (UAE). This news follows Diaverum’s acquisition by M42, the global health leader powered by AI and technology, that is building a network of world-class health providers to disrupt traditional healthcare models, and positively impact lives worldwide.
CKD is an escalating global health challenge, affecting approximately 10% of the world’s population, and projected to be the fifth leading cause of death by 2040. This trend is a specific concern in the UAE; according to the International Diabetes Federation, 16.4% of adults in the UAE suffer from diabetes, a leading cause of kidney failure. The country also faces challenges related to lifestyle factors, such as obesity, which can contribute to the rise in CKD.
As demand for specialised renal care in the country grows, Diaverum’s entry into the market comes with our commitment to forging a long-term presence within the UAE. We will put in place a resilient, patient-centric and AI-enabled renal care provision ecosystem to empower our healthcare professionals, address raising healthcare costs and supply chain issues alike, while delivering unparalleled levels of personalised care to CKD patients.
Our intent is not only to focus on offering a range of treatment options, encompassing both haemodialysis, holiday dialysis and home dialysis, but also to emphasise preventive care and education — key pillars in tackling the growing burden of CKD. Furthermore, we will be utilising M42's advanced global patient care platform, and digital & integrated health care capabilities, disrupting traditional renal care models towards precision and preventative care for longer, better lives. Such promise will be felt, for example, in our collaboration with M42’s Imperial College London Diabetes Centre (ICLDC), established in Abu Dhabi in 2006, to address the growing demand for diabetes care, a leading cause of CKD incidence.
Dimitris Moulavasilis, Diaverum’s CEO, commented: “We are delighted to bring Diaverum to Abu Dhabi and Al-Ain, and look forward to seeing it commence on-the-ground operations in the near future. Now well-established and integrated with the M42 Group, Diaverum is ideally positioned to take advantage of its portfolio’s combined health-tech capabilities, high standards of care delivery, multi-disciplinary services and international network, to transform the UAE’s CKD landscape, with its life-enhancing renal care offering”.
Ziyad Kabli, Diaverum’s COO for Middle East & Africa, added: “I am honoured to welcome the UAE to our Diaverum family. Today’s announcement marks a significant milestone in our mission to transform renal care worldwide, and grow our offering in the Middle East, a region that is feeling the escalating healthcare burden of CKD to patients, communities and national health care systems. By combining our excellence in care standards and expertise in AI-enabled, personalised renal care, with the integration of M42's extensive patient care platform & strong local presence, we have great ambitions to create a future-ready renal care landscape in the UAE, characterised by innovation, quality, and sustainability”.
This news sees Diaverum’s presence expand further within the GCC region; we are already present in Saudi Arabia, where 1,300 healthcare professionals care for 4,300 patients across 40 clinics in 33 cities, making us the largest provider of renal care in the Kingdom.